Does the media refer more to CCRN or EFX?

In the previous week, Equifax had 25 more articles in the media than Cross Country Healthcare. MarketBeat recorded 27 mentions for Equifax and 2 mentions for Cross Country Healthcare. Cross Country Healthcare's average media sentiment score of 0.96 beat Equifax's score of 0.66 indicating that Cross Country Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cross Country Healthcare 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equifax 7 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, APTV or EFX?

Equifax has lower revenue, but higher earnings than Aptiv. Equifax is trading at a lower price-to-earnings ratio than Aptiv, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptiv $20.66B 0.61 $165M $1.69 35.01 Equifax $6.07B 3.38 $660.30M $5.68 30.39

Is APTV or EFX more profitable?

Equifax has a net margin of 11.12% compared to Aptiv's net margin of 1.77%. Equifax's return on equity of 20.41% beat Aptiv's return on equity. Company Net Margins Return on Equity Return on Assets Aptiv 1.77% 17.83% 7.08% Equifax 11.12% 20.41% 8.27%

Does the media refer more to APTV or EFX?

In the previous week, Equifax had 20 more articles in the media than Aptiv. MarketBeat recorded 27 mentions for Equifax and 7 mentions for Aptiv. Equifax's average media sentiment score of 0.66 beat Aptiv's score of 0.51 indicating that Equifax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptiv 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equifax 7 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, G or EFX?

Equifax has higher revenue and earnings than Genpact. Genpact is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genpact $5.08B 1.02 $552.49M $3.26 9.35 Equifax $6.07B 3.38 $660.30M $5.68 30.39

Is G or EFX more profitable?

Equifax has a net margin of 11.12% compared to Genpact's net margin of 11.04%. Genpact's return on equity of 22.70% beat Equifax's return on equity. Company Net Margins Return on Equity Return on Assets Genpact 11.04% 22.70% 10.42% Equifax 11.12% 20.41% 8.27%

Does the media refer more to G or EFX?

In the previous week, Equifax had 15 more articles in the media than Genpact. MarketBeat recorded 27 mentions for Equifax and 12 mentions for Genpact. Equifax's average media sentiment score of 0.66 beat Genpact's score of 0.18 indicating that Equifax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genpact 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Equifax 7 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, EFX or IQV?

IQVIA has higher revenue and earnings than Equifax. IQVIA is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equifax $6.07B 3.38 $660.30M $5.68 30.39 IQVIA $16.31B 2.12 $1.36B $8.07 25.70

Is EFX or IQV more profitable?

Equifax has a net margin of 11.12% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Equifax's return on equity. Company Net Margins Return on Equity Return on Assets Equifax 11.12% 20.41% 8.27% IQVIA 8.33% 30.50% 6.53%

Does the media favor EFX or IQV?

In the previous week, Equifax had 13 more articles in the media than IQVIA. MarketBeat recorded 27 mentions for Equifax and 14 mentions for IQVIA. IQVIA's average media sentiment score of 1.10 beat Equifax's score of 0.66 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equifax 7 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Equifax (EFX) Competitors

$172.62 +6.18 (+3.71%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$172.58 -0.04 (-0.02%)

As of 04:02 AM Eastern

Compare

EFX vs. CCRN, CRAI, APTV, G, and IQV

Should you buy Equifax stock or one of its competitors? MarketBeat compares Equifax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Equifax include Cross Country Healthcare (CCRN), Charles River Associates (CRAI), Aptiv (APTV), Genpact (G), and IQVIA (IQV).

How does Equifax compare to Cross Country Healthcare?

Cross Country Healthcare (NASDAQ:CCRN) and Equifax (NYSE:EFX) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

96.0% of Cross Country Healthcare shares are owned by institutional investors. Comparatively, 96.2% of Equifax shares are owned by institutional investors. 6.3% of Cross Country Healthcare shares are owned by company insiders. Comparatively, 1.7% of Equifax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cross Country Healthcare presently has a consensus price target of $12.05, indicating a potential downside of 8.85%. Equifax has a consensus price target of $223.39, indicating a potential upside of 29.41%. Given Equifax's stronger consensus rating and higher possible upside, analysts plainly believe Equifax is more favorable than Cross Country Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cross Country Healthcare	1 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.90
Equifax	1 Sell rating(s)	5 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cross Country Healthcare has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Equifax has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

In the previous week, Equifax had 25 more articles in the media than Cross Country Healthcare. MarketBeat recorded 27 mentions for Equifax and 2 mentions for Cross Country Healthcare. Cross Country Healthcare's average media sentiment score of 0.96 beat Equifax's score of 0.66 indicating that Cross Country Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cross Country Healthcare	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equifax	7 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equifax has higher revenue and earnings than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cross Country Healthcare	$1.05B	0.41	-$94.85M	-$3.05	N/A
Equifax	$6.07B	3.38	$660.30M	$5.68	30.39

Equifax has a net margin of 11.12% compared to Cross Country Healthcare's net margin of -9.84%. Equifax's return on equity of 20.41% beat Cross Country Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cross Country Healthcare	-9.84%	-0.74%	-0.54%
Equifax	11.12%	20.41%	8.27%

Summary

Equifax beats Cross Country Healthcare on 14 of the 16 factors compared between the two stocks.

How does Equifax compare to Charles River Associates?

Equifax (NYSE:EFX) and Charles River Associates (NASDAQ:CRAI) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Equifax has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Charles River Associates has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Equifax presently has a consensus price target of $223.39, suggesting a potential upside of 29.41%. Charles River Associates has a consensus price target of $245.00, suggesting a potential upside of 44.96%. Given Charles River Associates' higher possible upside, analysts clearly believe Charles River Associates is more favorable than Equifax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equifax	1 Sell rating(s)	5 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.63
Charles River Associates	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Equifax has a net margin of 11.12% compared to Charles River Associates' net margin of 6.22%. Charles River Associates' return on equity of 26.02% beat Equifax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equifax	11.12%	20.41%	8.27%
Charles River Associates	6.22%	26.02%	8.35%

Equifax pays an annual dividend of $2.24 per share and has a dividend yield of 1.3%. Charles River Associates pays an annual dividend of $2.28 per share and has a dividend yield of 1.3%. Equifax pays out 39.4% of its earnings in the form of a dividend. Charles River Associates pays out 31.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Equifax has raised its dividend for 1 consecutive years and Charles River Associates has raised its dividend for 7 consecutive years. Charles River Associates is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

96.2% of Equifax shares are held by institutional investors. Comparatively, 84.1% of Charles River Associates shares are held by institutional investors. 1.7% of Equifax shares are held by insiders. Comparatively, 4.5% of Charles River Associates shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Equifax has higher revenue and earnings than Charles River Associates. Charles River Associates is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equifax	$6.07B	3.38	$660.30M	$5.68	30.39
Charles River Associates	$751.58M	1.45	$54.78M	$7.20	23.47

In the previous week, Equifax had 26 more articles in the media than Charles River Associates. MarketBeat recorded 27 mentions for Equifax and 1 mentions for Charles River Associates. Charles River Associates' average media sentiment score of 1.43 beat Equifax's score of 0.66 indicating that Charles River Associates is being referred to more favorably in the news media.

Company	Overall Sentiment
Equifax	Positive
Charles River Associates	Positive

Summary

Equifax beats Charles River Associates on 10 of the 19 factors compared between the two stocks.

How does Equifax compare to Aptiv?

Aptiv (NYSE:APTV) and Equifax (NYSE:EFX) are related large-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Aptiv currently has a consensus price target of $82.50, suggesting a potential upside of 39.44%. Equifax has a consensus price target of $223.39, suggesting a potential upside of 29.41%. Given Aptiv's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aptiv is more favorable than Equifax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptiv	2 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.83
Equifax	1 Sell rating(s)	5 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Equifax had 20 more articles in the media than Aptiv. MarketBeat recorded 27 mentions for Equifax and 7 mentions for Aptiv. Equifax's average media sentiment score of 0.66 beat Aptiv's score of 0.51 indicating that Equifax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptiv	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equifax	7 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aptiv pays an annual dividend of $0.88 per share and has a dividend yield of 1.5%. Equifax pays an annual dividend of $2.24 per share and has a dividend yield of 1.3%. Aptiv pays out 52.1% of its earnings in the form of a dividend. Equifax pays out 39.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Equifax has increased its dividend for 1 consecutive years.

Aptiv has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Equifax has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

94.2% of Aptiv shares are owned by institutional investors. Comparatively, 96.2% of Equifax shares are owned by institutional investors. 0.1% of Aptiv shares are owned by company insiders. Comparatively, 1.7% of Equifax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Equifax has lower revenue, but higher earnings than Aptiv. Equifax is trading at a lower price-to-earnings ratio than Aptiv, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptiv	$20.66B	0.61	$165M	$1.69	35.01
Equifax	$6.07B	3.38	$660.30M	$5.68	30.39

Equifax has a net margin of 11.12% compared to Aptiv's net margin of 1.77%. Equifax's return on equity of 20.41% beat Aptiv's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptiv	1.77%	17.83%	7.08%
Equifax	11.12%	20.41%	8.27%

Summary

Equifax beats Aptiv on 12 of the 19 factors compared between the two stocks.

How does Equifax compare to Genpact?

Genpact (NYSE:G) and Equifax (NYSE:EFX) are related companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Equifax has a net margin of 11.12% compared to Genpact's net margin of 11.04%. Genpact's return on equity of 22.70% beat Equifax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genpact	11.04%	22.70%	10.42%
Equifax	11.12%	20.41%	8.27%

Genpact has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Equifax has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

Genpact pays an annual dividend of $0.75 per share and has a dividend yield of 2.5%. Equifax pays an annual dividend of $2.24 per share and has a dividend yield of 1.3%. Genpact pays out 23.0% of its earnings in the form of a dividend. Equifax pays out 39.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Genpact has raised its dividend for 6 consecutive years and Equifax has raised its dividend for 1 consecutive years. Genpact is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Equifax has higher revenue and earnings than Genpact. Genpact is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genpact	$5.08B	1.02	$552.49M	$3.26	9.35
Equifax	$6.07B	3.38	$660.30M	$5.68	30.39

96.0% of Genpact shares are owned by institutional investors. Comparatively, 96.2% of Equifax shares are owned by institutional investors. 1.6% of Genpact shares are owned by company insiders. Comparatively, 1.7% of Equifax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Genpact currently has a consensus target price of $40.25, suggesting a potential upside of 31.98%. Equifax has a consensus target price of $223.39, suggesting a potential upside of 29.41%. Given Genpact's higher possible upside, analysts clearly believe Genpact is more favorable than Equifax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genpact	0 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.22
Equifax	1 Sell rating(s)	5 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Equifax had 15 more articles in the media than Genpact. MarketBeat recorded 27 mentions for Equifax and 12 mentions for Genpact. Equifax's average media sentiment score of 0.66 beat Genpact's score of 0.18 indicating that Equifax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genpact	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equifax	7 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Equifax beats Genpact on 13 of the 19 factors compared between the two stocks.

How does Equifax compare to IQVIA?

Equifax (NYSE:EFX) and IQVIA (NYSE:IQV) are related large-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Equifax has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Equifax presently has a consensus target price of $223.39, suggesting a potential upside of 29.41%. IQVIA has a consensus target price of $225.71, suggesting a potential upside of 8.83%. Given Equifax's higher probable upside, analysts plainly believe Equifax is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equifax	1 Sell rating(s)	5 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.63
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

Equifax has a net margin of 11.12% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Equifax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equifax	11.12%	20.41%	8.27%
IQVIA	8.33%	30.50%	6.53%

IQVIA has higher revenue and earnings than Equifax. IQVIA is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equifax	$6.07B	3.38	$660.30M	$5.68	30.39
IQVIA	$16.31B	2.12	$1.36B	$8.07	25.70

96.2% of Equifax shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 1.7% of Equifax shares are held by company insiders. Comparatively, 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Equifax had 13 more articles in the media than IQVIA. MarketBeat recorded 27 mentions for Equifax and 14 mentions for IQVIA. IQVIA's average media sentiment score of 1.10 beat Equifax's score of 0.66 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equifax	7 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Equifax beats IQVIA on 8 of the 15 factors compared between the two stocks.

Get Equifax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EFX vs. The Competition

Export

Metric	Equifax	Consulting Industry	Business Sector	NYSE Exchange
Market Cap	$19.82B	$3.96B	$6.90B	$23.46B
Dividend Yield	1.35%	2.70%	3.12%	4.02%
P/E Ratio	30.39	20.27	28.64	31.08
Price / Sales	3.38	1.93	344.87	19.77
Price / Cash	11.94	11.55	23.21	18.64
Price / Book	4.49	5.50	5.70	4.77
Net Income	$660.30M	$245.85M	$203.89M	$1.06B
7 Day Performance	-1.23%	0.90%	-1.60%	-0.23%
1 Month Performance	5.54%	-0.42%	-2.23%	-0.11%
1 Year Performance	-33.79%	-25.79%	13.25%	16.46%

Equifax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EFX Equifax	4.6553 of 5 stars	$172.62 +3.7%	$223.39 +29.4%	-33.3%	$19.82B	$6.07B	30.39	15,000	Upcoming Earnings
CCRN Cross Country Healthcare	1.9886 of 5 stars	$13.20 flat	$12.05 -8.7%	+9.5%	$426.49M	$1.05B	N/A	6,784
CRAI Charles River Associates	4.6305 of 5 stars	$149.95 +2.2%	$245.00 +63.4%	-14.2%	$969.13M	$770.71M	20.83	940	Positive News
APTV Aptiv	4.7379 of 5 stars	$59.78 +1.5%	$82.46 +37.9%	-14.5%	$12.65B	$20.40B	35.37	140,000	Analyst Forecast
G Genpact	4.9109 of 5 stars	$28.97 -0.4%	$43.29 +49.4%	-31.2%	$4.91B	$5.08B	8.89	146,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EFX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equifax (EFX) Competitors

EFX vs. CCRN, CRAI, APTV, G, and IQV

How does Equifax compare to Cross Country Healthcare?

Summary

How does Equifax compare to Charles River Associates?

Summary

How does Equifax compare to Aptiv?

Summary

How does Equifax compare to Genpact?

Summary

How does Equifax compare to IQVIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EFX vs. The Competition

Equifax Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equifax (EFX) Competitors

EFX vs. CCRN, CRAI, APTV, G, and IQV

How does Equifax compare to Cross Country Healthcare?

Do insiders & institutionals hold more shares of CCRN or EFX?

Do analysts prefer CCRN or EFX?

Which has more risk and volatility, CCRN or EFX?

Does the media refer more to CCRN or EFX?

Which has preferable earnings & valuation, CCRN or EFX?

Is CCRN or EFX more profitable?

Summary

How does Equifax compare to Charles River Associates?

Which has more volatility and risk, EFX or CRAI?

Do analysts rate EFX or CRAI?

Is EFX or CRAI more profitable?

Is EFX or CRAI a better dividend stock?

Do institutionals and insiders hold more shares of EFX or CRAI?

Which has stronger earnings & valuation, EFX or CRAI?

Does the media prefer EFX or CRAI?

Summary

How does Equifax compare to Aptiv?

Do analysts recommend APTV or EFX?

Does the media refer more to APTV or EFX?

Is APTV or EFX a better dividend stock?

Which has more volatility & risk, APTV or EFX?

Do institutionals and insiders believe in APTV or EFX?

Which has better valuation and earnings, APTV or EFX?

Is APTV or EFX more profitable?

Summary

How does Equifax compare to Genpact?

Is G or EFX more profitable?

Which has more volatility & risk, G or EFX?

Is G or EFX a better dividend stock?

Which has better valuation and earnings, G or EFX?

Do institutionals & insiders have more ownership in G or EFX?

Do analysts recommend G or EFX?

Does the media refer more to G or EFX?

Summary

How does Equifax compare to IQVIA?

Which has more risk & volatility, EFX or IQV?

Do analysts rate EFX or IQV?

Is EFX or IQV more profitable?

Which has better earnings & valuation, EFX or IQV?

Do institutionals and insiders believe in EFX or IQV?

Does the media favor EFX or IQV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EFX vs. The Competition

Equifax Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools